Judo Bio

Executive Summary

Judo Bio is a preclinical-stage biotechnology company pioneering kidney-targeted oligonucleotide therapeutics. Founded in 2021 and headquartered in San Diego, the company leverages its proprietary STRIKE platform to design ligand-siRNA conjugates that bind to recycling receptors on kidney cells, enabling efficient gene silencing for renal and systemic diseases. This targeted approach aims to overcome the limitations of conventional siRNA delivery, potentially offering safer and more effective treatments for conditions such as chronic kidney disease, polycystic kidney disease, and other renal disorders. By focusing on an underexplored organ with high medical need, Judo Bio differentiates itself within the RNA therapeutics landscape. While still in early development, Judo Bio's technology has attracted interest among investors and potential partners due to its innovative delivery mechanism and broad therapeutic applicability. The company is expected to advance its lead programs toward IND-enabling studies within the next 12–18 months. Key near-term milestones include securing Series A funding, nominating a development candidate, and generating compelling in vivo proof-of-concept data. Success in these areas could position Judo Bio as a leader in kidney-targeted gene silencing. However, the company faces typical preclinical risks, including off-target effects, immunogenicity, and manufacturing scalability. Overall, Judo Bio represents a promising, albeit early-stage, opportunity in the precision RNA therapeutics space.

Upcoming Catalysts (preview)

• Q2 2026Series A Financing Announcement70% success
• Q3 2026Lead Candidate Nomination60% success
• Q4 2026Preclinical Efficacy Data Presentation50% success